• Capio Biosciences

Start-up with UNC ties secures $2.9M to develop blood test for cancer

Updated: Dec 9, 2017

A start-up company co-founded by UNC Lineberger researcher Andrew Wang, MD, has raised $2.9 million to commercialize a test designed to capture cancer cells circulating in the blood.


January 5, 2017


Andrew Wang, MD, is a UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.








Media Contact: Laura Oleniacz, 919-445-4219, laura_oleniacz@med.unc.edu


A start-up company co-founded by a University of North Carolina Lineberger Comprehensive Cancer Center researcher has raised its first private investment to commercialize a test designed to detect and capture tumor cells (circulating tumor cells, or CTCs) in the blood.



Andrew Wang, MD, a UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology, co-founded Capio Biosciences, Inc., to develop the test in collaboration with Seungpyo Hong, PhD, a professor at the University of Wisconsin-Madison. Read more...


Need more details? Contact us.

 

We are here to assist. If you require further information or are interested in collaborations or partnerships, contact us by phone, email or via our social media channels.

* The CapioCyte System is currently under development and not for use in diagnostic procedures.

© COPYRIGHT 2017, 2018. ALL RIGHTS RESERVED. 

Capio and CapioCyte are trademarks of Capio Biosciences.

  • White LinkedIn Icon
  • White Twitter Icon
  • White Facebook Icon

505 S. Rosa Road
Suite 20A
Madison, WI 53719

info@capiobiosciences.com

608-441-8375